Advertisement
Advertisement

URGN

URGN logo

UroGen Pharma Ltd. Ordinary Shares

43.78
USD
Sponsored
+2.66
+6.47%
Jul 21, 16:00 UTC -4
Closed
exchange

After-Market

43.49

-0.29
-0.66%

URGN Earnings Reports

Positive Surprise Ratio

URGN beat 17 of 36 last estimates.

47%

Next Report

Date of Next Report
Aug 06, 2026
Estimate for Q2 26 (Revenue/ EPS)
$64.20M
/
-$0.30
Implied change from Q1 26 (Revenue/ EPS)
+25.98%
/
-36.17%
Implied change from Q2 25 (Revenue/ EPS)
+165.12%
/
-71.43%

UroGen Pharma Ltd. Ordinary Shares earnings per share and revenue

On May 06, 2026, URGN reported earnings of -0.47 USD per share (EPS) for Q1 26, beating the estimate of -0.49 USD, resulting in a 4.51% surprise. Revenue reached 50.96 million, compared to an expected 45.72 million, with a 11.47% difference. The market reacted with a +10.16% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of -0.30 USD, with revenue projected to reach 64.20 million USD, implying an decrease of -36.17% EPS, and increase of 25.98% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jul 09, 2026 For Q2 26
Estimate
-$0.73
Actual
-$0.81
Surprise
-10.78%
logo
DBV Technologies S.A.
Report Date
Jul 16, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.60
Surprise
-494.06%
logo
Lexaria Bioscience Corp. Common Stock
Report Date
Jul 13, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+7.73%
logo
VivoSim Labs, Inc. Common Stock
Report Date
Jul 14, 2026 For Q4 25
Estimate
-$0.19
Actual
-$2.21
Surprise
-1,040.35%
FAQ
For Q1 2026, UroGen Pharma Ltd. Ordinary Shares reported EPS of -$0.47, beating estimates by 4.51%, and revenue of $50.96M, 11.47% above expectations.
The stock price moved up 10.16%, changed from $23.83 before the earnings release to $26.25 the day after.
The next earning report is scheduled for Aug 06, 2026.
Based on 9 analysts, UroGen Pharma Ltd. Ordinary Shares is expected to report EPS of -$0.30 and revenue of $64.20M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement